CCB (00939.HK): RMB 70bn of 2026 Tier-2 Capital Bonds (Tranche 3) Issued
NewTimeSpace News: On 22 October 2026, China Construction Bank Corporation (the "Bank") announced that its 2025 second extraordinary general meeting held on 27 November 2025 had considered and approved the resolution on the issuance of capital instruments and total loss-absorbing capacity non-capital debt instruments, approving the issuance by the Bank of capital instruments and total loss-absorbing capacity (TLAC) non-capital debt instruments in an aggregate amount of not more than RMB 700 billion equivalent, of which capital instruments shall not exceed RMB 450 billion equivalent and TLAC non-capital debt instruments shall not exceed RMB 250 billion equivalent.
The announcement disclosed that, with the approval of the relevant regulatory authorities, the Bank has recently issued the China Construction Bank Corporation 2026 Tier-2 Capital Bonds (Tranche 3) (Bond Connect) (the "Bonds") in the national interbank bond market and completed the issuance on 21 October 2026. The Bonds were issued in an aggregate size of RMB 70 billion and comprise two tranches: Tranche 1 in an issue size of RMB 55 billion, being 10-year fixed-rate bonds with a conditional issuer redemption right at the end of the fifth year and a coupon rate of 1.74%; and Tranche 2 in an issue size of RMB 15 billion, being 15-year fixed-rate bonds with a conditional issuer redemption right at the end of the tenth year and a coupon rate of 1.93%.
The Bank stated that the proceeds from the Bonds will be used to replenish the Bank's Tier-2 capital in accordance with applicable laws and the approval of the regulatory authorities. The board of directors published this announcement on 22 October 2026.
- CONGYU INTE AGR (00875.HK): About 139.8mn Placing Shares Placed, Net Proceeds About HK$32.9mn
- SINO OIL & GAS (00702.HK): No Review of Delisting Decision; Listing to Be Cancelled from 27 October
- XUNFEIHEALTH (02506.HK): Spark Medical LLM V3.7 Released, Tops MedBench with a Composite Score of 99.6
- CSPC PHARMA (01093.HK): Phase III Trial of SYS6043 in First-Line Triple-Negative Breast Cancer Launched in China
- SWHY (06806.HK): SWHY Securities Completes RMB 1.8bn Perpetual Subordinated Bonds (Tranche 3) at 1.78%